Effects of the peripherally acting μ-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial

Cecilie Siggaard Knoph, Mathias Ellgaard Cook, Camilla Ann Fjelsted, Srdan Novovic, Michael Bau Mortensen, Liv Bjerre Juul Nielsen, Mark Berner Hansen, Jens Brøndum Frøkjær, Søren Schou Olesen, Asbjørn Mohr Drewes, Cecilie Siggaard Knoph, Mathias Ellgaard Cook, Camilla Ann Fjelsted, Srdan Novovic, Michael Bau Mortensen, Liv Bjerre Juul Nielsen, Mark Berner Hansen, Jens Brøndum Frøkjær, Søren Schou Olesen, Asbjørn Mohr Drewes

Abstract

Background: Moderate to severe acute pancreatitis (AP) is associated with a high rate of complications and increased mortality, yet no targeted pharmacologic treatment currently exists. As pain is a dominant symptom in AP, patients are exposed to excess levels of both endo- and exogenous opioids, which may have harmful effects on the course of AP. This trial investigates the effects of the peripherally acting μ-opioid receptor antagonist (PAMORA) methylnaltrexone on disease severity and clinical outcomes in patients with moderate to severe AP.

Methods: PAMORA-AP is a multicentre, investigator-initiated, double-blind, randomised, placebo-controlled, interventional trial, which will be conducted at four referral centres for acute pancreatitis in Denmark. Ninety patients with early-onset AP (pain onset within 48 h) as well as predicted moderate to severe disease (two or more systemic inflammatory response syndrome criteria upon admission) will be prospectively included. Subsequently, participants will be randomised (1:1) to intravenous treatment with either methylnaltrexone or matching placebo (Ringer's lactate) during 5 days of admission. The primary endpoint will be the group difference in disease severity as defined and measured by the Pancreatitis Activity Scoring System (PASS) score 48 h after randomisation. Secondary endpoints include daily PASS scores; disease severity according to the Atlanta classification; quantification of need for analgesics, nutritional support, intravenous fluid resuscitation and antibiotics; duration of hospital admissions, readmission rates and mortality. Pain intensity and gut function will be self-reported using validated questionnaires. Exploratory endpoints include circulating levels of pro-and anti-inflammatory markers, polyethylene glycol recovery from the urine, circulating levels of blood markers of intestinal permeability, the prevalence of pancreatic complications on computed tomography (CT) scans, and colon transit time assessed using a CT-based radiopaque marker method.

Discussion: This trial aims to evaluate the PAMORA methylnaltrexone as a novel targeted pharmacotherapy in patients with moderate to severe AP with the potential benefit of improved patient outcomes.

Trial registration: ClinicalTrials.gov NCT04743570 . Registered on 28 January 2021. EudraCT 2020-002313-18.

Keywords: Acute pancreatitis; Drug antagonism; Methylnaltrexone; Opioid antagonists; Randomised controlled trial; Treatment.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Effects of opioids on the gastrointestinal tract and immune system

References

    1. Kirkegård J, Mortensen FV, Heide-Jørgensen U, Cronin-Fenton D. Predictors of underlying pancreatic cancer in patients with acute pancreatitis: a Danish nationwide cohort study. HPB. 2020;22(4):553–562. doi: 10.1016/j.hpb.2019.08.013.
    1. Roberts SE, Morrison-Rees S, John A, Williams JG, Brown TH, Samuel DG. The incidence and aetiology of acute pancreatitis across Europe. Pancreatology. 2017;17(2):155–165. doi: 10.1016/j.pan.2017.01.005.
    1. Petrov MS, Shanbhag S, Chakraborty M, Phillips ARJ, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010;139(3):813–820. doi: 10.1053/j.gastro.2010.06.010.
    1. Schepers NJ, Bakker OJ, Besselink MG, Ahmed Ali U, Bollen TL, Gooszen HG, van Santvoort H, Bruno MJ, Dutch Pancreatitis Study Group Impact of characteristics of organ failure and infected necrosis on mortality in necrotising pancreatitis. Gut. 2019;68(6):1044–1051. doi: 10.1136/gutjnl-2017-314657.
    1. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet (London, England) 2015;386(9988):85–96. doi: 10.1016/S0140-6736(14)60649-8.
    1. Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, Banks PA. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol. 2009;7(11):1247–1251. doi: 10.1016/j.cgh.2009.08.012.
    1. Khanna AK, Meher S, Prakash S, Tiwary SK, Singh U, Srivastava A, Dixit VK. Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI Scores, IL-6, CRP, and procalcitonin in predicting severity, organ failure, pancreatic necrosis, and mortality in acute pancreatitis. HPB Surg. 2013;2013:1–10. doi: 10.1155/2013/367581.
    1. John BJ, Sambandam S, Garg P, Singh G, Kaur M, Baskaran R, et al. Persistent systemic inflammatory response syndrome predicts the need for tertiary care in acute pancreatitis. Acta Gastroenterol Belg. 2017;80(3):377–380.
    1. Working Group IAP/APA Acute Pancreatitis Guidelines IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1–15. doi: 10.1016/j.pan.2013.07.063.
    1. Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clin Issues. 2005;16(3):291–301. doi: 10.1097/00044067-200507000-00003.
    1. Basurto Ona X, Rigau Comas D, Urrútia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev. 2013;2013(7):CD009179.
    1. Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol. 2010;23(5):616–622. doi: 10.1097/ACO.0b013e32833c3473.
    1. Drewes AM, Munkholm P, Simrén M, Breivik H, Kongsgaard UE, Hatlebakk JG, Agreus L, Friedrichsen M, Christrup LL. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J pain. 2016;11(1):111–122. doi: 10.1016/j.sjpain.2015.12.005.
    1. Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R, et al. Morphine Induces Bacterial Translocation in Mice by Compromising Intestinal Barrier Function in a TLR-Dependent Manner. PLoS One. 2013;8(1):e54040.
    1. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2008;2(1):14–18. doi: 10.1097/SPC.0b013e3282f5272e.
    1. Plein LM, Rittner HL. Opioids and the immune system – friend or foe. Br J Pharmacol. 2018;175(14):2717–2725. doi: 10.1111/bph.13750.
    1. Nee J, Rangan V, Lembo A. Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract. Neurogastroenterol Motil. 2018;30(5):e13367. doi: 10.1111/nmo.13367.
    1. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542–1550. doi: 10.1016/j.pain.2013.04.024.
    1. Grønlund D, Poulsen JL, Krogh K, Brock C, Liao D, Gregersen H, Drewes AM, Olesen AE. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction. Eur J Pharm Sci. 2018;117(January):187–192. doi: 10.1016/j.ejps.2018.02.008.
    1. Poulsen JL, Mark EB, Brock C, Frøkjær JB, Krogh K, Drewes AM. Colorectal transit and volume during treatment with prolonged-release oxycodone/naloxone versus oxycodone plus macrogol 3350. J Neurogastroenterol Motil. 2018;24(1):119–127. doi: 10.5056/jnm17058.
    1. Poulsen JL, Brock C, Grønlund D, Liao D, Gregersen H, Krogh K, Drewes AM. Prolonged-release oxycodone/naloxone improves anal sphincter relaxation compared to oxycodone plus macrogol 3350. Dig Dis Sci. 2017;62(11):3156–3166. doi: 10.1007/s10620-017-4784-7.
    1. Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(11):2032–2038. doi: 10.1093/annonc/mdw317.
    1. Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–358. doi: 10.2147/CEG.S52097.
    1. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997;121(4):834–840. doi: 10.1038/sj.bjp.0701138.
    1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS, Acute Pancreatitis Classification Working Group Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111. doi: 10.1136/gutjnl-2012-302779.
    1. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol. 2007;42(2):101–119. doi: 10.1007/s00535-006-1945-4.
    1. Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet (London, England) 2020;396(10252):726–734. doi: 10.1016/S0140-6736(20)31310-6.
    1. Yuan C-S, Doshan H, Charney MR, O’connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005;45(5):538–546. doi: 10.1177/0091270004273491.
    1. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343. doi: 10.1056/NEJMoa0707377.
    1. EMA. Annex I: Summary of product characteristics. In: Relistor : EPAR - Product Information. 2008. information_en.pdf. Accessed 13 September 2021.
    1. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain. 2006;10(4):353–361. doi: 10.1016/j.ejpain.2005.06.002.
    1. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. doi: 10.3109/00365529709011203.
    1. Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl. 1996;221:8–13. doi: 10.3109/00365529609095544.
    1. Galipeau HJ, Verdu EF. The complex task of measuring intestinal permeability in basic and clinical science. Neurogastroenterol Motil. 2016;28(7):957–965. doi: 10.1111/nmo.12871.
    1. Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA, Fischer K, Timmerman HM, Ahmed Ali U, Cirkel GA, Bollen TL, van Ramshorst B, Schaapherder AF, Witteman BJ, Ploeg RJ, van Goor H, van Laarhoven C, Tan AC, Brink MA, van der Harst E, Wahab PJ, van Eijck C, Dejong CH, van Erpecum K, Akkermans LM, Gooszen HG, Dutch Acute Pancreatitis Study Group Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg. 2009;250(5):712–719. doi: 10.1097/SLA.0b013e3181bce5bd.
    1. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol. 2003;38(1):36–42. doi: 10.1080/00365520310000410.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
    1. European Commision. EudraLex, Volume 4. In: Annex 13. 2010. . Accessed 13 September 2021.
    1. Wu BU, Batech M, Quezada M, Lew D, Fujikawa K, Kung J, Jamil LH, Chen W, Afghani E, Reicher S, Buxbaum J, Pandol SJ. Dynamic Measurement of Disease Activity in Acute Pancreatitis: The Pancreatitis Activity Scoring System. Am J Gastroenterol. 2017;112(7):1144–1152. doi: 10.1038/ajg.2017.114.
    1. Buxbaum J, Quezada M, Chong B, Gupta N, Yu CY, Lane C, da B, Leung K, Shulman I, Pandol S, Wu B. The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study. Am J Gastroenterol. 2018;113(5):755–764. doi: 10.1038/s41395-018-0048-1.
    1. Paragomi P, Tuft M, Pothoulakis I, Singh VK, Stevens T, Nawaz H, et al. Dynamic changes in the pancreatitis activity scoring system during hospital course in a multicenter, prospective cohort. J Gastroenterol Hepatol. 2021:1–8.
    1. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB, National Institutes of Health, National Heart, Lung, and Blood Institute ARDS Network Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132(2):410–417. doi: 10.1378/chest.07-0617.
    1. Pandharipande PP, Shintani AK, Hagerman HE, St Jacques PJ, Rice TW, Sanders NW, Ware LB, Bernard GR, Ely EW. Derivation and validation of Spo2/Fio2 ratio to impute for Pao2/Fio2 ratio in the respiratory component of the Sequential Organ Failure Assessment score. Crit Care Med. 2009;37(4):1317–1321. doi: 10.1097/CCM.0b013e31819cefa9.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95(May):103208. doi: 10.1016/j.jbi.2019.103208.
    1. European Organization For Nuclear Research. Zenodo. 2013. . Accessed 13 September 2021.
    1. Vege SS. Clinical manifestations and diagnosis of acute pancreatitis. In: UpToDate®. 2019. =default&display_rank=2. Accessed 13 September 2021.
    1. Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology. 2015;149(6):1490–1500.e1. doi: 10.1053/j.gastro.2015.07.066.
    1. Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28(1):26–35. doi: 10.1111/nmo.12716.
    1. Barlass U, Dutta R, Cheema H, George J, Sareen A, Dixit A, Yuan Z, Giri B, Meng J, Banerjee S, Banerjee S, Dudeja V, Dawra RK, Roy S, Saluja AK. Morphine worsens the severity and prevents pancreatic regeneration in mouse models of acute pancreatitis. Gut. 2018;67(4):600–602. doi: 10.1136/gutjnl-2017-313717.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren